Skip to main content
SpringerLink
Log in

Meningococcal Vaccines and Vaccine Developments

  • Protocol
Meningococcal Vaccines

Part of the book series: Methods in Molecular Medicine™ ((MIMM,volume 66))

Abstract

Despite rapid advances in the diagnosis of bacterial infections and the availability of effective antibiotics, meningococcal disease continues to represent a substantial public health problem for most countries (1–4). Disease usually develops rapidly, is notoriously difficult to distinguish from other febrile illnesses, and generally has a high case-fatality rate. The death of an otherwise fit and healthy individual can occur within a very short time from the first appearance of symptoms, those who survive frequently suffer from permanent tissue damage and neurological problems (4,5). Consequently, the development and implementation of effective immunoprophylaxis is a sine qua non for the comprehensive control of meningococcal disease. From an historical perspective, many meningococcal vaccines have been developed and evaluated in clinical trials; unfortunately, no vaccine so far offers comprehensive protection. This overview traces the development of the existing licensed vaccines and examines the prospects of vaccine candidates that are currently under development or subject to clinical evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    *

    Recent estimates based on surveillance during the first 9 mo following the introduction of the serogroup C conjugate in England indicate that the short-term efficacy of the vaccine was 97% (95% CI 77–99) for teenagers and 92% (65–98) for toddlers (Ramsay, Andrews, Kaczmarski and Miller, 2001, Lancet 357, 195, 196).

References

  1. Cartwright, K. A. V. (1995) Meningococcal Disease. John Wiley and Sons, Chichester, UK.

    Google Scholar 

  2. Tzeng, Y. and Stephens, D. S. (2000) Epidemiology and pathogenesis of Neisseria meningitidis. Microbes. Infect. 2, 687–700.

    Article  CAS  PubMed  Google Scholar 

  3. Schwartz, B., Moore, P. S., and Broome, C. V. (1989) Global epidemiology of meningococcal disease. Clin. Microbiol. Rev. 2, s118–s124.

    PubMed  Google Scholar 

  4. Peltola, H. (1983) Meningococcal disease: still with us. Rev. Infect. Dis. 5, 71–91.

    CAS  PubMed  Google Scholar 

  5. Steven, N. and Wood, M. (1995) The clinical spectrum of meningococcal disease, in Meningococcal Disease (Cartwright, K., ed.), John Wiley and Sons, Chichester, UK, pp. 177–205.

    Google Scholar 

  6. Cartwright, K. A. V. (1995) Meningococcal carriage and disease, in Meningococcal Disease (Cartwright, K. A. V., ed.), John Wiley and Sons, Chichester, UK, pp. 115–146.

    Google Scholar 

  7. Jones, D. M. (1995) Epidemiology of meningococcal disease in Europe and the USA, in Meningococcal Disease (Cartwright, K. A. V., ed.), John Wiley and Sons, Chichester, UK, pp. 147–157.

    Google Scholar 

  8. Reingold, A. L., Broome, C. V., Ajello, G. W., Hightower, A. W., Bolan, G. A., Adamsbaum, C., et al. (1985) Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet ii, 114–118.

    Article  Google Scholar 

  9. Wyle, F. A., Artenstein, M. S., Brandt, B. L., Tramont, E. C., Kasper, D. L., Altieri, P. L., et al. (1972) Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect. Dis. 126, 514–521.

    CAS  PubMed  Google Scholar 

  10. Finne, J., Leinonen, M., and Makela, P. H. (1983) Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet ii, 355–357.

    Article  Google Scholar 

  11. Poolman, J. T. (1995) Development of a meningococcal vaccine. Infect. Agents Dis. 4, 13–28.

    CAS  PubMed  Google Scholar 

  12. Zollinger, W. D. (1997) New and Improved Vaccines Against Meningococcal Disease, in New Generation Vaccines (Levine, M. M., Woodrow, G. C., Kaper, J. B., and Cobon, G. S., eds.), Marcel Dekker, New York, pp. 469.

    Google Scholar 

  13. Maiden, M. C. J. and Feavers, I. M. (1995) Population genetics and global epidemiology of the human pathogen Neisseria meningitidis, in Population Genetics of Bacteria (Baumberg, S., Young, J. P. W., Saunders, J. R., and Wellington, E. M. H., eds.), Cambridge University Press, Cambridge, UK, pp. 269–293.

    Google Scholar 

  14. Stephens, D. S. (1999) Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 353, 941–942.

    Article  CAS  PubMed  Google Scholar 

  15. Maiden, M. C. and Spratt, B. G. (1999) Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 354, 615–616.

    Article  CAS  PubMed  Google Scholar 

  16. Frosch, M. and Meyer, T. F. (1992) Transformation-mediated exchange of virulence determinants by co-cultivation of pathogenic Neisseriae. FEMS Microbiol. Lett. 100, 345–349.

    Google Scholar 

  17. Wang, J.-F., Caugant, D. A., Morelli, G., Koumaré, B., and Achtman, M. (1993) Antigenic and epidemiological properties of the ET-37 complex of Neisseria meningitidis. J Infect. Dis. 167, 1320–1329.

    CAS  PubMed  Google Scholar 

  18. Hammerschmidt, S., Hilse, R., van Putten, J. P., Gerardy Schahn, R., Unkmeir, A., and Frosch, M. (1996) Modulation of cell surface sialic acid expression in Neisseria meningitidis via a transposable genetic element. EMBO J. 15, 192–198.

    CAS  PubMed  Google Scholar 

  19. Hammerschmidt, S., Muller, A., Sillmann, H., Muhlenhoff, M., Borrow, R., Fox, A., et al. (1996) Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol. Microbiol. 20, 1211–1220.

    Article  CAS  PubMed  Google Scholar 

  20. Jennings, M. P., Srikhanta, Y. N., Moxon, E. R., Kramer, M., Poolman, J. T., Kuipers, B., and van der Ley, P. (1999) The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis. Microbiology 145, 3013–3021.

    CAS  PubMed  Google Scholar 

  21. van der Ende, A., Hopman, C. T., Zaat, S., Essink, B. B., Berkhout, B., and Dankert, J. (1995) Variable expression of class 1 outer membrane protein in Neisseria meningitidis is caused by variation in the spacing between the-10 and-35 regions of the promoter. J. Bacteriol. 177, 2475–2480.

    PubMed  Google Scholar 

  22. Tettelin, H., Saunders, N. J., Heidelberg, J., Jeffries, A. C., Nelson, K. E., Eisen, J. A., et al. (2000) Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287, 1809–1815.

    Article  CAS  PubMed  Google Scholar 

  23. Frasch, C. E., Zollinger, W. D., and Poolman, J. T. (1985) Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev. Infect. Dis. 7, 504–510.

    CAS  PubMed  Google Scholar 

  24. Abdillahi, H. and Poolman, J. T. (1987) Whole-cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol. Lett. 48, 367–371.

    Article  Google Scholar 

  25. Vedros, N. A. (1987) Development of meningococcal serogroups, in Evolution of Meningococcal Disease. (Vedros, N. A., ed.), CRC Press, Boca Raton, FL, pp. 33–37.

    Google Scholar 

  26. Tsai, C. M., Mocca, L. F., and Frasch, C. E. (1987) Immunotype epitopes of Neisseria meningitidis lipooligosaccharide types 1 through 8. Infect. Immun. 55, 1652–1656.

    CAS  PubMed  Google Scholar 

  27. Frasch, C. E. (1995) Meningococcal vaccines: past, present and future, in Meningococcal Disease (Cartwright, K., ed.), John Wiley and Sons, Chichester, UK, pp. 245–284.

    Google Scholar 

  28. Wright, A. E. (1897) Remarks on vaccination against typhoid fever. BMJ 1, 256–259.

    Article  PubMed  Google Scholar 

  29. Underwood, E. A. (1940) Recent knowledge of the incidence and control of cerebospinal fever. BMJ i, 757–763.

    Article  Google Scholar 

  30. Kuhns, D. (1936) The control of meningococcic meningitis epidemics by active immunization with meningococcus soluble toxin: a preliminary report. JAMA 107, 5–11.

    Google Scholar 

  31. Kuhns, D., Kisner, P., Williams, M. P., and Moorman, P. L. (1938) The control of meningococcic meningitis epidemics by active immunization with meningococcus soluble toxin: further studies. JAMA 110, 484–487.

    Google Scholar 

  32. MacLeod, C. M., Hodges, R. G., Heidelberger, M., and Bernhard, W. G. (1945) Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82, 445–465.

    Article  Google Scholar 

  33. Gotschlich, E. C., Liu, T. Y., and Artenstein, M. S. (1969) Human immunity to the meningococcus. III. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J. Exp. Med. 129, 1349–1365.

    Article  CAS  PubMed  Google Scholar 

  34. Gotschlich, E. C., Goldschneider, I., and Artenstein, M. S. (1969) Human immunity to the meningococcus IV. Immunogenicity of group A and group C meningococcal polysaccharides. J. Exp. Med. 129, 1367–1384.

    Article  CAS  PubMed  Google Scholar 

  35. Artenstein, M. S., Gold, R., Zimmerly, J. G., Wyle, F. A., Schneider, H., and Harkins, C. (1970) Prevention of meningococcal disease by group C polysaccharide vaccine. New England J. Med. 282, 417–420.

    Article  CAS  Google Scholar 

  36. Peltola, H., Makela, H., Kayhty, H., Jousimies, H., Herva, E., Hallstrom, K., et al. (1977) Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. New Engl. J. Med. 297, 686–691.

    Article  CAS  PubMed  Google Scholar 

  37. Gold, R., Lepow, M. L., Goldschneider, I., Draper, T. L., and Gotschlich, E. C. (1975) Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants. J. Clin. Invest. 56, 1536–1547.

    Article  CAS  PubMed  Google Scholar 

  38. Adams, W. G., Deaver, K. A., Cochi, S. L., Plikaytis, B. D., Zell, E. R., Broome, C. V., and Wenger, J. D. (1993) Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 269, 221–226.

    Article  CAS  PubMed  Google Scholar 

  39. Jennings, H. J. and Lugowski, C. (1982) Immunochemistry of groups A, B and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 127, 1011–1018.

    Google Scholar 

  40. Beuvery, E. C., Miedema, F., van Delft, R. W., Haverkamp, J., Leussink, A. B., te Pas, B. J., et al. (1983) Preparation and physicochemical and immunological characterisation of polysaccharide-outer membrane protein complexes of Neisseria meningitidis. Infect. Immun. 40, 369–380.

    CAS  PubMed  Google Scholar 

  41. Costantino, P., Viti, S., Podda, A., Velmonte, M. A., Nencioni, L., and Rappuoli, R. (1992) Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10, 691–698.

    Article  CAS  PubMed  Google Scholar 

  42. Campagne, G., Garba, A., Fabre, P., Schuchat, A., Ryall, R., Boulanger, D., Bybel, M., et al. (2000) Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr. Infect. Dis. J. 19, 144–150.

    Article  CAS  PubMed  Google Scholar 

  43. Leach, A., Twumasi, P. A., Kumah, S., Banya, W. S., Jaffar, S., Forrest, B. D., et al. (1997) Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175, 200–204.

    CAS  PubMed  Google Scholar 

  44. Lieberman, J. M., Chiu, S. S., Wong, V. K., Partridge, S., Chang, S.-J., Chiu, C.-Y., et al. (1996) Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. JAMA 275, 1499–1503.

    Article  CAS  PubMed  Google Scholar 

  45. MacDonald, N. E., Halperin, S. A., Law, B. J., Forrest, B., Danzig, L. E., and Granoff, D. M. (1998) Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 280, 1685–1689.

    Article  CAS  PubMed  Google Scholar 

  46. Richmond, P., Goldblatt, D., Fusco, P. C., Fusco, J. D., Heron, I., Clark, S., et al. (1999) Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 18, 641–646.

    Article  CAS  PubMed  Google Scholar 

  47. Twumasi, P. A., Jr., Kumah, S., Leach, A., O’Dempsey, T. J., Ceesay, S. J., Todd, J., et al. (1995) A trial of a group A plus group C meningococcal polysaccharideprotein conjugate vaccine in African infants. J. Infect. Dis. 171, 632–638.

    PubMed  Google Scholar 

  48. Fairley, C. K., Begg, N., Borrow, R., Fox, A. J., Jones, D. M., and Cartwright, K. (1996) Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. 174, 1360–1363.

    CAS  PubMed  Google Scholar 

  49. Richmond, P., Borrow, R., Miller, E., Clark, S., Sadler, F., Fox, A., et al. (1999) Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J. Infect. Dis. 179, 1569–1572.

    Article  CAS  PubMed  Google Scholar 

  50. Kayhty, H., Karanko, V., Peltola, H., Sarna, S., and Makela, P. H. (1980) Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J. Infect. Dis. 142, 861–868.

    CAS  PubMed  Google Scholar 

  51. Lepow, M. L., Beeler, J., Randolph, M., Samuelson, J. S., and Hankins, W. A. (1986) Reactogenicity and immunogenicity of a quadravalent combined meningococcal polysaccharide vaccine in children. J. Infect. Dis. 154, 1033–1036.

    CAS  PubMed  Google Scholar 

  52. Goldschneider, I., Gotschlich, E. C., and Artenstein, M. S. (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129, 1307–1326.

    Article  CAS  PubMed  Google Scholar 

  53. Figueroa, J., Andreoni, J., and Densen, P. (1993) Complement deficiency states and meningococcal disease. Immunol. Res. 12, 295–311.

    Article  CAS  PubMed  Google Scholar 

  54. Lepow, M. L., Goldschneider, I., Gold, R., Randolph, M., and Gotschlich, E. C. (1977) Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines. Pediatrics 60, 673–680.

    CAS  PubMed  Google Scholar 

  55. Goldblatt, D. (1998) immunization and the maturation of infant immune responses. Dev. Biol. Stand. 95, 125–132.

    CAS  PubMed  Google Scholar 

  56. WHO (2000) Health conditions for travellers to Saudi Arabia. Wkly. Epidemiol. Record 75, 7–8.

    Google Scholar 

  57. Begg, N. (1995) Outbreak Management, in Meningococcal Disease (Cartwright, K., ed.), John Wiley and Sons, Chichester, UK, pp. 285–305.

    Google Scholar 

  58. Greenwood, B. M. and Wali, S. S. (1980) Control of meningococcal infection in the African meningitis belt by selective vaccination. Lancet 1, 729–732.

    Article  CAS  PubMed  Google Scholar 

  59. Mohammed, I., Obineche, E. N., Onyemelukwe, G. C., and Zaruba, K. (1984) Control of epidemic meningococcal meningitis by mass vaccination. I. Further epidemiological evaluation of groups A and C vaccines in northern Nigeria. J. Infect. 9, 190–196.

    Article  CAS  PubMed  Google Scholar 

  60. Eskola, J., Takala, A. K., and Kayhty, H. (1993) Haemophilus influenzae type b polysaccharide-protein conjugate vaccines in children. Curr. Opin. Pediatr. 5, 55–59.

    Article  CAS  PubMed  Google Scholar 

  61. Moxon, E. R., Heath, P. T., Booy, R., Azzopardi, H. J., Slack, M. P., and Ramsay, M. E. (1999) 4th European conference on vaccinology: societal value of vaccination. The impact of Hib conjugate vaccines in preventing invasive H. influenzae diseases in the UK. Vaccine 17, S11–S13.

    Article  PubMed  Google Scholar 

  62. Goldblatt, D. (1998) Recent developments in bacterial conjugate vaccines. J. Med. Microbiol. 47, 563–567.

    Article  CAS  PubMed  Google Scholar 

  63. Lipsitch, M. (1999) Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg. Infect. Dis. 5, 336–345.

    Article  CAS  PubMed  Google Scholar 

  64. Caugant, D. A., Mocca, L. F., Frasch, C. E., Froholm, L. O., Zollinger, W. D., and Selander, R. K. (1987) Genetic structure of Neisseria meningitidis populations in relation to serogroup, serotype, and outer membrane protein pattern. J. Bacteriol. 169, 2781–2792.

    CAS  PubMed  Google Scholar 

  65. Swartley, J. S., Marfin, A. A., Edupuganti, S., Liu, L. J., Cieslak, P., Perkins, B., et al. (1997) Capsule switching of Neisseria meningitidis. Proc. Natl. Acad. Sci. USA 94, 271–276.

    Article  CAS  PubMed  Google Scholar 

  66. Borrow, R., Fox, A. J., Cartwright, K., Begg, N. T., and Jones, D. M. (1999) Salivary antibodies following parenteral immunization of infants with a meningococcal serogroup A and C conjugated vaccine. Epidemiol. Infect. 123, 201–208.

    Article  CAS  PubMed  Google Scholar 

  67. Finne, J. and Makela, P. H. (1985) Cleavage of the polysialosyl units of brain glycoproteins by a bacteriophage endosialidase. Involvement of a long oligosaccharide segment in molecular interactions of polysialic acid. J. Biol. Chem. 260, 1265–1270.

    CAS  PubMed  Google Scholar 

  68. Jennings, H. J., Roy, R., and Gamian, A. (1986) Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol. 137, 1708–1713.

    CAS  PubMed  Google Scholar 

  69. Fusco, P. C., Michon, F., Tai, J. Y., and Blake, M. S. (1998) Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and non-human primates. J. Infect. Dis. 175, 364–372.

    Google Scholar 

  70. Sierra, G. V., Campa, H. C., Varcacel, N. M., Garcia, I. L., Izquierdo, P. L., Sotolongo, P. F., et al. (1991) Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH. Ann. 14, 195–207.

    CAS  PubMed  Google Scholar 

  71. Bjune, G., Hoiby, E. A., Gronnesby, J. K., Arnesen, O., Fredriksen, J. H., Halstensen, A., et al. (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338, 1093–1096.

    Article  CAS  PubMed  Google Scholar 

  72. de Kleijn, E. D., de Groot, R., Labadie, J., Lafeber, A. B., van den So, D. G., van Alphen, L., et al. (2000) Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine 18, 1456–1466.

    Article  PubMed  Google Scholar 

  73. Boslego, J., Garcia, J., Cruz, C., Zollinger, W., Brandt, B., Ruiz, S., et al. (1995) Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13, 821–829.

    Article  CAS  PubMed  Google Scholar 

  74. Frasch, C. E. and Peppler, M. S. (1982) Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens. Infect. Immun. 37, 271–280.

    CAS  PubMed  Google Scholar 

  75. Haneberg, B., Dalseg, R., Wedege, E., Hoiby, E. A., Haugen, I. L., Oftung, F., et al. (1998) Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect. Immun. 66, 1334–1341.

    CAS  PubMed  Google Scholar 

  76. de Moraes, J. C., Perkins, B. A., Camargo, M. C., Hidalgo, N. T., Barbosa, H. A., Sacchi, C. T., et al. (1992) Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340, 1074–1078.

    Article  PubMed  Google Scholar 

  77. Tappero, J. W., Lagos, R., Ballesteros, A. M., Plikaytis, B., Williams, D., Dykes, J., et al. (1999) Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281, 1520–1527.

    Article  CAS  PubMed  Google Scholar 

  78. Tsai, C.-M., Frasch, C. E., and Mocca, L. F. (1981) Five structural classes of major outer membrane proteins in Neisseria meningitidis. J. Bacteriol. 146, 69–78.

    CAS  PubMed  Google Scholar 

  79. Guttormsen, H.-K., Wetzler, L. M., and Solberg, C. O. (1994) Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease. Infect. Immuni. 62, 1437–1443.

    CAS  Google Scholar 

  80. Wedege, E. and Froholm, L. O. (1986) Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect. Immun. 51, 571–578.

    CAS  PubMed  Google Scholar 

  81. Feavers, I. M., Fox, A. J., Gray, S., Jones, D. M., and Maiden, M. C. (1996) Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design. Clin. Diagn. Lab. Immunol. 3, 444–450.

    CAS  PubMed  Google Scholar 

  82. van der Ley, P. and Poolman, J. T. (1992) Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect. Immun. 60, 3156–3161.

    Google Scholar 

  83. van der Ley, P., van der Biezen, J., and Poolman, J. T. (1995) Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13, 401–407.

    Article  CAS  PubMed  Google Scholar 

  84. Claassen, I., Meylis, J., van der Ley, P., Peeters, C., Brons, H., Robert, J., et al. (1996) Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14, 1001–1008.

    Article  CAS  PubMed  Google Scholar 

  85. Cartwright, K., Morris, R., Rumke, H., Fox, A., Borrow, R., Begg, N., et al. (1999) Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17, 2612–2619.

    Article  CAS  PubMed  Google Scholar 

  86. van der Voort, E. R., van Dijken, H., Kuipers, B., van der Biezen, J., van der Ley, P., Meylis, J., et al. (1997) Human B-and T-cell responses after immunization with a hexavalent PorA meningococcal outer membrane vesicle vaccine. Infect. Immun. 65, 5184–5190.

    PubMed  Google Scholar 

  87. Danve, B., Lissolo, L., Guinet, F., Boutry, E., Speck, D., Cadoz, M., et al. (1998) Safety and immunogenicity of a Neisseria meningitidis group B transferrin binding protein vaccine in adults, in Eleventh International Pathogenic Neisseria Conference (Nassif, X., Quentin-Millet, M. J., and Taha, M. K., eds.), EDK, Paris, pp. 53–53.

    Google Scholar 

  88. Danve, B., Lissolo, L., Mignon, M., Dumas, P., Colombani, S., Schryvers, A. B., and Quentin-Millet, M. J. (1993) Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine 11, 1214–1220.

    Article  CAS  PubMed  Google Scholar 

  89. Parkhill, J., Achtman, M., James, K. D., Bentley, S. D., Churcher, C., Klee, S. R., et al. (2000) Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 404, 502–506.

    Article  CAS  PubMed  Google Scholar 

  90. Pizza, M., Scarlato, V., Masignani, V., Giuliani, M. M., Arico, B., Comanducci, M., et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287, 1816–1820.

    Article  CAS  PubMed  Google Scholar 

  91. Gu, X. X. and Tsai, C.-M. (1993) Preparation, characterisation and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates. Infect. Immun. 61, 1873–1880.

    CAS  PubMed  Google Scholar 

  92. Jennings, H. J., Lugowski, C., and Ashton, F. E. (1984) Conjugation of meningococcal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B N. meningitidis. Infect. Immun. 43, 407–412.

    CAS  PubMed  Google Scholar 

  93. Verheul, A. F. M., Snippe, H., and Poolman, J. T. (1993) Meningococcal lipopolysaccharides: virulence factor and potential vaccine component. Microbiol. Rev. 57, 34–45.

    CAS  PubMed  Google Scholar 

  94. DiFabio, J. L., Michon, F., Brisson, J.-R., and Jennings, H. J. (1990) Structure of the L1 and L6 core oligosaccharide epitopes of Neisseria meningitidis. Can. J. Chemi. 68, 1029–1034.

    Article  CAS  Google Scholar 

  95. Jennings, H. J., Beurret, M., Gamian, A., and Michon, F. (1987) Structure and immunochemistry of meningococcal lipopolysaccharides. Antonie van Leeuwenhoek 53, 519–522.

    Article  CAS  PubMed  Google Scholar 

  96. Kogan, G., Uhrin, D., Brisson, J. R., and Jennings, H. J. (1997) Structural basis of the Neisseria meningitidis immunotypes including the L4 and L7 immunotypes. Carbohydr. Res. 298, 191–199.

    Article  CAS  PubMed  Google Scholar 

  97. Verheul, A. F., Boons, G. J., van der Marel, G. A., van Boom, J. H., Jennings, H. J., Snippe, H., et al. (1991) Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3, 7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates. Infect. Immun. 59, 3566–3573.

    CAS  PubMed  Google Scholar 

  98. Scholten, R. J., Kuipers, B., Valkenburg, H. A., Dankert, J., Zollinger, W. D., and Poolman, J. T. (1994) Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J. Med. Microbiol. 41, 236–243.

    Article  CAS  PubMed  Google Scholar 

  99. Jones, D. M., Borrow, R., Fox, A. J., Gray, S., Cartwright, K. A., and Poolman, J. T. (1992) The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb. Pathog. 13, 219–224.

    Article  CAS  PubMed  Google Scholar 

  100. Zollinger, W. D. and Moran, E. (1991) Meningococcal vaccines-present and future. Trans. R. Soc. Trop. Med. Hyg. 85(Suppl. 1), 37–43.

    Article  PubMed  Google Scholar 

  101. Estabrook, M., Mandrell, R. E., Apicella, M. A., and Griffiss, J. M. (1990) Measurement of the human response to meningococcal lipooligosaccharide antigens by using serum to inhibit monoclonal antibody binding to purified lipooligosaccharide. Infect. Immun. 58, 2204–2213.

    CAS  PubMed  Google Scholar 

  102. Pincus, S. H., Smith, M. J., Jennings, H. J., Burritt, J. B., and Glee, P. M. (1998) Peptides that mimic the group B streptococcal type III capsular polysaccharide antigen. J. Immunol. 160, 293–298.

    CAS  PubMed  Google Scholar 

  103. De, B. X, Laurent, T., Tibor, A., Godfroid, F., Weynants, V., Letesson, J. J., and Mertens, P. (1999) Antigenic properties of peptidic mimics for epitopes of the lipopolysaccharide from Brucella. J. Mol. Biol. 294, 181–191.

    Article  CAS  Google Scholar 

  104. Westerink, M. A. J., Giardina, P. C., Apicella, M. A., and Kieber-Emmons, T. (1995) Peptide mimicry of the meningococcal group C capsular polysaccharide. Proc. Natl. Acad Sci. USA 92, 4021–4025.

    Article  CAS  PubMed  Google Scholar 

  105. Westerink, M. A., Giardina, P. C., Apicella, M. A., and Kieber-Emmons, T. (1995) Peptide mimicry of the meningococcal group C capsular polysaccharide. Proc. Natl. Acad. Sci. USA 92, 4021–4025.

    Article  CAS  PubMed  Google Scholar 

  106. Grothaus, M. C., Srivastava, N., Smithson, S. L., Kieber-Emmons, T., Williams, D. B., Carlone, G. M., and Westerink, M. A. (2000) Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine 18, 1253–1263.

    Article  CAS  PubMed  Google Scholar 

  107. Moe, G. R., Tan, S., and Granoff, D. M. (1999) Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention of Neisseria meningitidis serogroup B disease. FEMS Immunol. Med. Microbiol. 26, 209–226.

    Article  CAS  PubMed  Google Scholar 

  108. Gold, R., Goldschneider, I., Lepow, M. L., Draper, T. F., and Randolph, M. (1978) Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J. Infect. Dis. 137, 112–121.

    CAS  PubMed  Google Scholar 

  109. Troncoso, G., Sanchez, S., Moreda, M., Criado, M. T., and Ferreiros, C. M. (2000) Antigenic cross-reactivity between outer membrane proteins of Neisseria meningitidis and commensal Neisseria species. FEMS Immunol. Med. Microbiol. 27, 103–109.

    Article  CAS  PubMed  Google Scholar 

  110. Griffiss, J. M., Yamasaki, R., Estabrook, M., and Kim, J. J. (1991) Meningococcal molecular mimicry and the search for an ideal vaccine. Trans. R. Soc. Trop. Med. Hyg. 85(Suppl. 1), 32–36.

    Article  PubMed  Google Scholar 

  111. Maslanka, S. E., Gheesling, L. L., Libutti, D. E., Donaldson, K. B., Harakeh, H. S., Dykes, J. K., et al. (1997) Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin. Diagn. Lab. Immunol. 4, 156–167.

    CAS  PubMed  Google Scholar 

  112. Goldschneider, I., Gotschlich, E. C., and Artenstein, M. S. (1969) Human immunity to the meningococcus. II. Development of natural immunity. J. Exp. Med. 129, 1327–1348.

    Article  CAS  PubMed  Google Scholar 

  113. Cadieux, N., Plante, M., Rioux, C. R., Hamel, J., Brodeur, B. R., and Martin, D. (1999) Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect. Immun. 67, 4955–4959.

    CAS  PubMed  Google Scholar 

  114. Pintor, M., Gomez, J. A., Ferron, L., Ferreiros, C. M., and Criado, M. T. (1998) Analysis of TbpA and TbpB functionality in defective mutants of Neisseria meningitidis. J. Med. Microbiol. 47, 757–760.

    Article  CAS  PubMed  Google Scholar 

  115. Ala’Aldeen, D. A., Davies, H. A., and Borriello, S. P. (1994) Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes. Vaccine 12, 535–541.

    Article  PubMed  Google Scholar 

  116. Christodoulides, M., Brooks, J. L., Rattue, E., and Heckels, J. E. (1998) Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology 144, 3027–3037.

    Article  CAS  PubMed  Google Scholar 

  117. Christodoulides, M. and Heckels, J. E. (1994) Immunization with a multiple antigen peptide containing defined B-and T-cell epitopes: production of bactericidal antibodies against group B Neisseria meningitidis. Microbiology 140, 2951–2960.

    Article  CAS  PubMed  Google Scholar 

  118. Kizil, G., Todd, I., Atta, M., Borriello, S. P., Ait-Tahar, K., and Ala’Aldeen, D. A. (1999) Identification and characterization of TspA, a major CD4(+) T-celland B-cell-stimulating Neisseria-specific antigen. Infect. Immun. 67, 3533–3541.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Bacteriology, National Institute of Biological Standards & Control, Hertfordshire, UK

    Ian M. Feavers

Authors
  1. Ian M. Feavers
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. BC Research Institute for Children’s and Women’s Health, Vancouver, BC, Canada

    Andrew J. Pollard MD, PhD

  2. Wellcome Trust Centre for the Epidemiology of Infectious Disease, Oxford, UK

    Martin C.J. Maiden PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Humana Press Inc., Totowa, NJ

About this protocol

Cite this protocol

Feavers, I.M. (2001). Meningococcal Vaccines and Vaccine Developments. In: Pollard, A.J., Maiden, M.C. (eds) Meningococcal Vaccines. Methods in Molecular Medicine™, vol 66. Humana Press. https://doi.org/10.1385/1-59259-148-5:1

Download citation

  • DOI: https://doi.org/10.1385/1-59259-148-5:1

  • Publisher Name: Humana Press

  • Print ISBN: 978-0-89603-801-1

  • Online ISBN: 978-1-59259-148-0

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation